Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625060 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
A Phase 2 study of Chronic Migraine and Episodic Migraine, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 641
- Enrollment target
- 20
- Study locations
NCT06625060: Recruiting Phase 2 study of Chronic Migraine and Episodic Migraine, sponsored by Ipsen.
NCT06625060 is a Phase 2 study of Chronic Migraine and Episodic Migraine that is actively recruiting participants, run by Ipsen. The registered enrollment target is 641 participants, above the 306-participant average among 17 other Chronic Migraine trials with a reported enrollment target (109% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625060, a Phase 2 study of Chronic Migraine and Episodic Migraine, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 641 participants
- Enrollment target
- 20
- Study locations
Study Summary
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of IPN10200 to inject at each point, * The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.
Primary Outcome
An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is an AE for which the start date is on or after the date that the intervention began.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL IPN10200
- BIOLOGICAL IPN10200 dose A
- BIOLOGICAL IPN10200 dose B
Study Locations (20)
California
- Axiom Research, LLC - Apple Valley
- Profound Research. LLC - NCSC - Carlsbad
- M3Wake -PRI Encino - Encino
- WR-PRI Encino - Encino
- Neuro-Pain Medical Center - Fresno
- Fullerton Neurological Center - Neurology - Fullerton
- Neurology Center of North Orange County - Fullerton
- University of California, Irvine - Department of Neurology - Irvine
- Kaizen Brain Center - La Jolla
- Pharmacology Research Institute (PRI) - Los Alamitos
- Pharmacology Research Institute (PRI) - Los Alamitos/Long Beach - Newport Beach
- Profound Research, LLC - Pasadena
- Acclaim Clinical Research - Internal Medicine - San Diego
- Clinical Trials Management LLC - Thousand Oaks
- Alliance Clinical West Hills (Focus Clinical Research) - West Hills
Alabama
- Central Research Associates - Birmingham
- Rehabilitation & Neurological Services, LLC - Huntsville
Arizona
- MD First Research - Chandler - Neurology - Chandler
- MD First Research - Chandler - Chandler
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-06-15 |
| Phase | Phase 2 |
What NCT06625060 shows while recruiting
NCT06625060 is an interventional study that assigns participants to a tested intervention. The registered 641 participants enrollment target is mid-sized for trials with a published cap, above the 306-participant average among 17 other Chronic Migraine trials with a reported enrollment target (109% higher).
The record links to 2 conditions, with Chronic Migraine appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06625060 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT06625060 about?
NCT06625060 is a clinical study titled "A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults". A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which ...
What is the current status of trial NCT06625060?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 641 participants. The study started on 2024-10-10. Estimated completion is 2027-06-15.
What conditions does trial NCT06625060 study?
This clinical trial studies the following conditions: Chronic Migraine, Episodic Migraine.
What interventions are being tested in trial NCT06625060?
The interventions under investigation include: Placebo (OTHER), IPN10200 (BIOLOGICAL), IPN10200 dose A (BIOLOGICAL), IPN10200 dose B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06625060?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625060 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625060's enrollment target sits among peer trials
641 5th of 17 higher than 13 of 17 other Chronic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOTOX® vs. XEOMIN® for Chronic Migraine
RECRUITING · Phase 3
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA
RECRUITING
-
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
RECRUITING · NA
-
Acceptance and Commitment Therapy to Improve Disability in Chronic Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06319820 · 641 participants · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI